We are live on ! Find out more
SLS icon

SELLAS Life Sciences

34 hedge funds and large institutions have $4.57M invested in SELLAS Life Sciences in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,396% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $84K

0% less ownership

Funds ownership: 0.02%0.01% (-0%)

9% less capital invested

Capital invested by funds: $5.02M → $4.57M (-$453K)

32% less funds holding

Funds holding: 5034 (-16)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

70% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 23

Holders
34
Holders Change
-16
Holders Change %
-32%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
6
Reduced
11
Closed
23
Calls
$1.26M
Puts
$84K
Net Calls
+$1.17M
Net Calls Change
-$65K
Name Holding Trade Value Shares
Change
Change in
Stake
QCG
51
Quadrant Capital Group
Ohio
-$3K -3 Closed
Legal & General Group
52
Legal & General Group
United Kingdom
-$1K -1 Closed
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
-$870 -1 Closed
Simplex Trading
54
Simplex Trading
Illinois
+$870 +1 New

SLS Hedge Fund Activity: Q2 2017 in Review

34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2017, worth a combined $4.57M — down 9% from $5.02M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of SLS and 7 opened new positions — a net loss of 16 holders — while 11 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $360K. The largest seller was BlackRock, cutting an estimated $318K.

  • 34 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2017, down from 50 in Q1 2017.
  • Funds reported $4.57M of SELLAS Life Sciences stock for Q2 2017, down 9% quarter-over-quarter.
  • 7 funds opened new SELLAS Life Sciences positions in Q2 2017 and 23 closed out, a net change of -16 holders.
  • The largest SELLAS Life Sciences buyer in Q2 2017 was Renaissance Technologies, an estimated $360K added.
  • The largest SELLAS Life Sciences seller in Q2 2017 was BlackRock, an estimated $318K sold.

Based on aggregated 13F filings for Q2 2017.